Philip Donenberg
Director/Board Member at AVROBIO, INC.
Net worth: 378 031 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Sean Nolan | M | 56 |
Jaguar Gene Therapy LLC
 Jaguar Gene Therapy LLC Medical/Nursing ServicesHealth Services Jaguar Gene Therapy LLC is a company that aims to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company is based in Lake Forest, IL. The company's unrelenting commitment is to advocate boldly and care fiercely for patients and families. The company works together to confront the challenges of treating complex diseases and are advancing their initial pipeline that targets diseases with significant unmet need in sizeable patient populations. Joseph Nolan has been the CEO of the company since 2020. | 8 years |
| Sukumar Nagendran | M | 58 |
Jaguar Gene Therapy LLC
Jaguar Gene Therapy LLC Medical/Nursing ServicesHealth Services Jaguar Gene Therapy LLC is a company that aims to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company is based in Lake Forest, IL. The company's unrelenting commitment is to advocate boldly and care fiercely for patients and families. The company works together to confront the challenges of treating complex diseases and are advancing their initial pipeline that targets diseases with significant unmet need in sizeable patient populations. Joseph Nolan has been the CEO of the company since 2020.
RestorGenex Corp.
 RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 7 years |
| Erik Ostrowski | M | 51 | 5 years | |
| Joseph Nolan | M | 61 |
Jaguar Gene Therapy LLC
Jaguar Gene Therapy LLC Medical/Nursing ServicesHealth Services Jaguar Gene Therapy LLC is a company that aims to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company is based in Lake Forest, IL. The company's unrelenting commitment is to advocate boldly and care fiercely for patients and families. The company works together to confront the challenges of treating complex diseases and are advancing their initial pipeline that targets diseases with significant unmet need in sizeable patient populations. Joseph Nolan has been the CEO of the company since 2020. | 4 years |
| Steven Avruch | M | 63 | 5 years | |
| Fred Porter | M | - | - | |
| Kamran Alam | M | 46 | 4 years | |
| Laura Sepp-Lorenzino | M | 63 | 4 years | |
| Christopher Paige | M | 71 | 8 years | |
| Ian Clark | M | 62 | 6 years | |
| Annalisa Jenkins | M | 58 | 6 years | |
| Sean Stalfort | M | 53 | 1 years | |
| Azadeh Golipour | M | - | 8 years | |
| Philip Vickers | M | 64 | 5 years | |
| Bruce Booth | M | 49 | 8 years | |
| Glen Tullman | M | 64 |
7wire Ventures LLC
 7wire Ventures LLC Investment ManagersFinance 7wire Ventures LLC (7wire ventures) is a venture capital firm founded in 2011 by Matthew A. Tullman and Glen E. Tullman. The firm is headquartered in Chicago, Illinois. | 11 years |
| David Greenwald | M | - |
Jaguar Gene Therapy LLC
Jaguar Gene Therapy LLC Medical/Nursing ServicesHealth Services Jaguar Gene Therapy LLC is a company that aims to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company is based in Lake Forest, IL. The company's unrelenting commitment is to advocate boldly and care fiercely for patients and families. The company works together to confront the challenges of treating complex diseases and are advancing their initial pipeline that targets diseases with significant unmet need in sizeable patient populations. Joseph Nolan has been the CEO of the company since 2020. | 4 years |
| Sean McAuliffe | M | - | 4 years | |
| Essra Ridha | M | 41 | 3 years | |
| Kirsten Dupuis | F | - | 8 years | |
| Alison Long | M | 61 | 1 years | |
| Scott Gottesman | M | - | - | |
| Elise Wang | F | 64 |
Jaguar Gene Therapy LLC
Jaguar Gene Therapy LLC Medical/Nursing ServicesHealth Services Jaguar Gene Therapy LLC is a company that aims to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company is based in Lake Forest, IL. The company's unrelenting commitment is to advocate boldly and care fiercely for patients and families. The company works together to confront the challenges of treating complex diseases and are advancing their initial pipeline that targets diseases with significant unmet need in sizeable patient populations. Joseph Nolan has been the CEO of the company since 2020. | 4 years |
| David Fellows | M | 67 |
Jaguar Gene Therapy LLC
Jaguar Gene Therapy LLC Medical/Nursing ServicesHealth Services Jaguar Gene Therapy LLC is a company that aims to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company is based in Lake Forest, IL. The company's unrelenting commitment is to advocate boldly and care fiercely for patients and families. The company works together to confront the challenges of treating complex diseases and are advancing their initial pipeline that targets diseases with significant unmet need in sizeable patient populations. Joseph Nolan has been the CEO of the company since 2020. | 4 years |
| Emily McGinnis | F | - | 4 years | |
| Tracy M. Porter | F | - | 3 years | |
| Anita Treohan | F | - | - | |
| Gail Farfel | M | 60 | 4 years | |
| Andrew Knudten | M | - |
Jaguar Gene Therapy LLC
Jaguar Gene Therapy LLC Medical/Nursing ServicesHealth Services Jaguar Gene Therapy LLC is a company that aims to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company is based in Lake Forest, IL. The company's unrelenting commitment is to advocate boldly and care fiercely for patients and families. The company works together to confront the challenges of treating complex diseases and are advancing their initial pipeline that targets diseases with significant unmet need in sizeable patient populations. Joseph Nolan has been the CEO of the company since 2020. | 4 years |
| Jim Rouse | M | - | - | |
| James Marken | M | 61 | 17 years | |
| Mary Newman | F | 65 | 3 years | |
| Robert Garber | M | 53 |
7wire Ventures LLC
7wire Ventures LLC Investment ManagersFinance 7wire Ventures LLC (7wire ventures) is a venture capital firm founded in 2011 by Matthew A. Tullman and Glen E. Tullman. The firm is headquartered in Chicago, Illinois. | 10 years |
| Hayleigh Collins | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Stephen Simes | M | 72 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL.
Unimed Pharmaceuticals LLC
 Unimed Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Unimed Pharmaceuticals, Inc. manufactured pharmaceutical products. It provided multiple indications in the therapeutic areas of cardiology, men's health, HIV and other infectious diseases. The company was founded in 1999 and was headquartered in Marietta, GA. | 22 years |
| R. Session | M | 45 | 6 years | |
| Paul Manning | M | 68 | 8 years | |
| Geoff MacKay | M | 57 | 8 years | |
| Kim Lee | M | - | - | |
| August Moretti | M | 73 |
Assertio Therapeutics, Inc.
 Assertio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL. | 6 years |
| Arthur S. Przybyl | M | 67 | 11 years | |
| Charlotte C. Arnold | F | 59 | 7 years | |
| Kim Warren | M | - | 5 years | |
| Timothy Boris | M | 55 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 4 years |
| Rob W. Schrepfer | M | 52 | - | |
| Nelson K. Stacks | M | 53 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | - |
| David G. Kalergis | M | 75 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | - |
| David Sherris | M | 71 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 2 years |
| Michael C. Snabes | M | 75 | 8 years | |
| Ross J. Mangano | M | 78 | 2 years | |
| Bong Koh | M | - | - | |
| Timothy J. Douros | M | - | - | |
| Yael Schwartz | M | 75 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 1 years |
| Joshua Resnick | M | 49 | 2 years | |
| Katina Dorton | F | 66 | 1 years | |
| Lisa Deschamps | F | 52 | 3 years | |
| Christopher Mason | M | 66 | 7 years | |
| Claire Aldridge | M | - | 1 years | |
| Kathleen Reape | M | 58 | 3 years | |
| Joanne Zborowski | F | - | - | |
| John L. Gainer | M | 85 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | - |
| Edward C. Rosenow | M | 89 | 16 years | |
| Carole Nüchterlein | F | 62 | 3 years | |
| Sol Barer | M | 76 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 3 years |
| John T. Potts | M | 92 | 4 years | |
| Isaac Blech | M | 73 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 3 years |
| Jonathan Leff | M | 55 | 3 years | |
| Peter Kjaer | M | 64 | - | |
| Steven J. Bell | M | - | - | |
| Thomas Penn | M | 78 | 11 years | |
| Daniel Welch | M | 66 | 2 years | |
| Louis Sullivan | M | 90 | 19 years | |
| Terrence Kearney | M | 69 | 2 years | |
| Fred Holubow | M | 85 | 19 years | |
| Stephen Sherwin | M | 75 | 4 years | |
| Tracy Marshbanks | M | 60 | 12 years | |
| Rex Bright | M | 84 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 2 years |
| Jerold Howard Rubinstein | M | 86 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | 3 years |
| Frank Verwiel | M | 61 | 3 years | |
| Scott Requadt | M | 56 | 2 years | |
| Georgette Verdin | F | - | - | |
| Joao Siffert | M | 60 | 1 years | |
| Fariborz Kamal | M | 61 | 1 years | |
| Diana M. Escolar | M | 52 | - | |
| Greg Gara | M | - | 3 years | |
| Petra Kaufmann | M | 58 | 2 years | |
| Kim Raineri | M | - | 2 years | |
| Patricia Fuller | F | - | - | |
| Holly May | F | - | - | |
| Gabriel Cohn | M | 65 | 2 years | |
| Rick Modi | M | 55 | 2 years | |
| Françoise de Craecker | F | 62 | 1 years | |
| Birgitte Volck | M | 61 | 2 years | |
| Sandra J. Croak-Brossman | M | - | - | |
| Jeffrey W. Winkelman | M | - | - | |
| David R. Jones | M | 60 |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | - |
| William D. Milling | M | - | - | |
| Deanna M. Petersen | F | 62 | 7 years | |
| Thomas Joseph Dee | M | 60 | 2 years | |
| Christopher Gerry | M | - | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Philip Donenberg
- Personal Network
